Swiss eye-care company Alcon (NYSE:ALC) has signed a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for roughly $770 million. The deal, which is expected to boost Alcon’s financials, is in sync with its initiatives to expand its ophthalmic pharmaceutical offerings. Through this transaction, Aerie’s Rocklatan, Rhopressa and AR-15512 will become a part of Alcon’s portfolio. Notably, AR-15512 is currently a Phase 3 product candidate for treating dry eye disease. Further, Aerie’s pipeline of drugs, comprising multiple clinical and preclinical ophthalmic pharmaceutical product candidates, will also come under Alcon post the deal. Coming to the financial terms of the deal, Alcon is acquiring at a price of $15.
https://www.tipranks.com/news/what-does-aerie-buyout-mean-for-alcon-nysealc?utm_source=advfn.com&utm_medium=referral
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Nov 2022 até Dez 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Dez 2021 até Dez 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.